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ABSTRACT 
Background: Frailty is a state of increased vulnerability to poor resolution of homeostasis as 
a consequence of age-related decreased physiological reserves. Although physical frailty and 
cognitive impairment have been shown to be associated, evidence on the prevalence of frailty 
in Alzheimer’s disease is scarce. 
Objective: To conduct a systematic review on the prevalence of frailty and to combine the 
data to synthesize the pooled prevalence of physical frailty among patients with Alzheimer’s 
disease. 
Method: Five electronic databases (Embase, MEDLINE, CINAHL Plus, PsycINFO, and the 
Cochrane Library) were searched for studies providing cross-sectional data on physical frailty 
among patients with Alzheimer’s disease published from 2000 to January 2016.  
Results:  Of 2,564 studies identified through the systematic review, five studies incorporating 
534 patients with Alzheimer’s disease were included for the meta-analysis. The prevalence of 
frailty varied with a wide range from 11.1% to 50.0% and the pooled prevalence was 31.9% 
(five studies, 95% confidence interval (CI)=15.7%-48.5%). The high degree of heterogeneity 
was observed in all analyses. A borderline publication bias was detected. 
Conclusion: The current study showed that frailty is highly prevalent in older patients with 
Alzheimer’s disease in the community with the pooled prevalence of 31.9%. The true 
prevalence may be much higher given that end-stage patients may not be included. This 
information is important for clinicians and researchers. 
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INTRODUCTION 
Frailty is defined as a state of increased vulnerability and poor resolution of homeostasis after 
a stressor event as a consequence of age-related decreased physiological reserves.[1] Frail 
individuals are at increased risk of falls, disability, hospitalization, institutionalization, 
fracture, a poor quality of life, and death.[1-7] Despite an increasing amount of evidence on 
frailty in the literature, there has been no international consensus on how best to 
operationalize frailty.[8] The most popular criteria to operationalize frailty is the so-called 
frailty phenotype proposed by Fried at al. using the Cardiovascular Health Study (CHS).[9] 
In this operationalization, frailty is characterized by only physical components, including 
unintentional weight loss, self-reported exhaustion, weakness, slow walking speed, and low 
physical activity.[9]  
 
Although the CHS criteria remain the most frequently used,[10] there has been considerable 
debate on whether, in addition to physical components, other features, such as cognitive, 
psychological, and social factors, should be included in the conceptualization of frailty to 
capture the heterogeneous elderly population more holistically and identify at-risk individuals 
more precisely.[8] Multiple studies have shown cross-sectional and prospective associations 
of frailty with cognitive impairment and dementia.[11; 12] In one cross-sectional study of 
Japanese community-dwelling older people, those with both physical frailty and cognitive 
impairment had the highest disability risks in most instrumental activities of daily living 
(IADL) compared with those with either, one or none of these factors.[13] Another 
longitudinal study using the Three-City Study cohort showed that adding cognitive 
impairment to physical frailty improved the predictive abilities for incident disability, 
hospitalization, and mortality.[14] Therefore, cognition has increasingly been recognized as a 
component of frailty,[8; 15] and some of the multidimensional frailty criteria have already 
included cognitive impairment.[16] Furthermore, there is an emerging new concept, 
“cognitive frailty”, which was first proposed by an international consensus group organized 
by the International Academy on Nutrition and Aging and the International Association of 
Gerontology and Geriatrics, as a clinical manifestation characterized by the co-existence of 
physical frailty and cognitive impairment without dementia.[17]  
 
In a previous systematic review, the overall weighted prevalence of frailty was reported to be 
10.7% with a considerably wide range from 4.0% to 59.1% in older people over 65 years old 
in the community.[18] The prevalence increases as people age, and up to one-fourth of people 
aged 85 years and older are frail.[18; 19] Frailty has been predominantly studied in general 
elderly populations, and selected populations, such as patients with dementia, are relatively 
understudied with scarce evidence in the literature. Therefore, the overall prevalence of 
frailty among this highly heterogeneous dementia population is unknown. Although one 
could argue that all patients with dementia could be classified as being frail or pre-frail if 
cognitive impairment was a frailty component, it is also evident that some patients with 
dementia remain physically fit even when severely impaired cognitively. Dementia is defined 
as loss of memory and one other cognitive function, sufficient to cause impairment in 
everyday functioning, and is therefore by definition a cause of disability but not necessarily 
of frailty. Conversely, physical frailty was shown to be a significant predictor of newly 
developing dementia in a recent systematic review and meta-analysis.[12] 
 
Given that we expect an increasing number of patients with dementia as the world population 
ages,[20] estimating the overall prevalence of frailty among older people with Alzheimer’s 
disease, which is the most common cause of dementia,[21] is of great importance. The aims 
of this study were two-fold: (1) to conduct a systematic search of the literature on the frailty 
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status of community-dwelling older people with Alzheimer’s disease and (2) to combine the 
data on prevalence of frailty to synthesize the pooled estimates. 
 
METHOD 
Data Sources and Search Strategy 
A systematic literature search was conducted in January 2016 based on a protocol developed 
according to Preferred Reporting Items for Systematic Review and Meta-Analyses 
(PRISMA)[22] and Meta-analysis of Observational Studies in Epidemiology (MOOSE)[23] 
statements. The protocol has been registered at PROSPERO website.[24] Five electronic 
databases (Embase, MEDLINE, CINAHL Plus, PsycINFO, and the Cochrane Library) were 
searched for studies published in 2000 or later with an explosion function if available and 
without language restriction. A combination of Medical Subject Headings (MeSH) and text 
words were used as: 
(Dementia (MeSH)) OR (Alzheimer(’s) Disease (MeSH)) OR (Dementia with Lewy Bodies 
(MeSH)) OR (Lewy Body Disease (MeSH)) OR (Multiinfarct Dementia (MeSH)) OR 
(Dementia, Multi-Infarct (MeSH)) OR (Vascular Dementia (MeSH)) OR (Dementia, Vascular 
(MeSH)) OR (Frontotemporal Dementia (MeSH)) OR (Frontal Variant Frontotemporal 
Dementia (MeSH)) OR (Dementia, Senile (MeSH)) OR (Senile Dementia (MeSH)) OR 
(Presenile Dementia (MeSH)) OR (Dementia, Presenile (MeSH)) OR (Delirium, Dementia, 
Amnestic, Cognitive Disorders (MeSH)) OR (dementia) OR (alzheimer) 
AND 
(Frail Elderly (MeSH)) OR (Frailty Syndrome (MeSH)) OR (Frailty). 
Relevant studies and related review articles were used for additional studies; their 
bibliographies were reviewed and studies displayed as “Similar articles” by PubMed when 
the relevant studies were searched were also examined. 
 
Study Selection 
Studies were considered potentially eligible and included if they (1) included patients with 
Alzheimer’s disease based on established diagnostic criteria, such as the National Institute of 
Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) criteria or the Diagnostic and Statistical Manual 
of Mental Disorders in the community with a mean age of 65 years and older, (2) used a 
cross-sectional design or observational design with baseline data, (3) provided prevalence of 
frailty and/or pre-frailty or sufficient data to calculate prevalence of frailty, and (4) defined 
and categorized frailty by validated criteria based on physical components, such as CHS 
criteria, the Study of Osteoporotic Fractures (SOF) criteria or their modified versions. Studies 
were excluded if they (1) used population without Alzheimer’s disease or did not provide data 
only on individuals with Alzheimer’s disease, (2) did not used validated frailty criteria or 
used continuous index to describe frailty, such as the Frailty Index (FI) and did not categorize 
frailty status, or (3) were a randomized controlled trial, review article, editorial, comment, or 
personal opinion. Mild cognitive impairment was not considered in this study. If multiple 
studies used the same cohort, the one with the largest sample size was included. Two 
researchers (GK and AL) independently screened the titles, abstracts, and full-texts of the 
studies identified by the systematic literature search for eligibility. Disagreements were 
solved by discussion. 
 
Data Extraction 
The data extracted from the included studies were first author, study cohort name, publication 
year, location, sample size and description, age (mean and range or age criterion for 
inclusion), proportion of female participants, frailty criteria, diagnostic criteria, and numbers 
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and percentages of frail, pre-frail, and robust participants. Authors of the potentially eligible 
studies were contacted for additional data. 
 
Methodological Quality Assessment 
Methodological quality of all eligible studies was examined using the six criteria from a tool 
for critically assessing studies on prevalence or incidence as an outcome.[25] Studies were 
considered to have adequate quality in terms of methodology if the studies meet three of 
more criteria. 
 
Statistical Analysis 
Numbers of the entire cohort and those who were classified as being robust (or non-frail), 
pre-frail, and frail were extracted directly from the studies or attempts were made to obtain 
data by contacting the authors. Heterogeneity across the studies was assessed using a chi-
square test and was considered to be present if p<0.05. The degree of the heterogeneity was 
assessed using I2 statistic. The heterogeneity was considered as high, moderate, and low when 
I2 values were 75%, 50%, and 25%, respectively.[26] Pooled prevalence of being robust, pre-
frail, and frail along with 95% confidence intervals (CI) were calculated using a random-
effects model if heterogeneity was present and using a fixed-effects model if heterogeneity 
was absent. Begg-Mazumdar’s and Egger’s tests were used for possible publication bias. All 
statistical analyses were conducted using StatsDirect (ver. 2.8, StatsDirect, Cheshire, UK). 
Statistical significance was set at p value of less than 0.05. 
 
RESULTS 
Selection Process 
The systematic search of the literature using the five electronic databases yielded 2,564 
citations, and two additional studies were identified from other relevant studies. From the 
2,566 studies, 832 duplicate studies and 1,713 studies that were considered to be not relevant 
were excluded, leaving 21 studies for full-text review. Nine studies were excluded for being 
editorial, review, comment, or poster abstracts; three for using the same cohorts; and two 
each for not categorizing frailty status and not showing data of interest. The five studies 
remaining were considered to have adequate methodological quality and were included in a 
meta-analysis (Tables 1 and 2). Figure 1 shows a flowchart of the study selection. 
 
Study Characteristics 
The study characteristics of all the included studies[27-31] are summarized in Table 1. All 
studies were published only recently between 2012 and 2016. Study locations were Italy,[27; 
30] Singapore,[31] Finland,[28] and the Netherlands.[29] The smallest and largest sample 
sizes were 38[30] and 207.[29] Two types of data were found: data of patients with 
Alzheimer’s disease from a large population-based study[28; 30] and data of participants 
recruited from a specialty healthcare service (e.g. memory clinic).[27; 29; 31] The diagnostic 
criteria used were NINCDS-ADRDA criteria[29-31] or the Diagnostic and Statistical Manual 
of Mental Disorders 4th edition (DMS-IV).[27; 28] The mean age ranged from 73.1[30] to 
82.8[27] years. The proportion of female participants was from 45.2%[30] to 77.1%.[27] 
Modified versions of CHS and SOF criteria were used by four studies[28-31] and one 
study,[27] respectively. Three studies used three frailty categories (robust, pre-frail, and 
frail),[27-29] while two used dichotomized categories (non-frail and frail).[30; 31] Both 
Begg-Mazumdar’s and Egger’s tests detected a borderline publication bias. 
 
Prevalence of Frailty 
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The prevalence of frailty varied widely from study to study with a range from 11.1%[29] to 
50.0%[30] and its pooled prevalence was 31.9% (five studies, 95%CI=15.7%-48.5%). 
Among these, three studies[27-29] provided three frailty categories (frailty, pre-frailty, and 
robustness), which were used to calculated pooled prevalence of pre-frailty and robustness, 
and two studies[30; 31] provided two frailty categories (frailty and robustness). The pooled 
prevalence of pre-frailty and robustness was 41.4% (three studies, 95%CI=28.3%-55.2%) and 
29.0% (three studies, 95%CI=18.4%-40.9%), respectively. The pooled prevalence of frailty 
recalculated using the three studies providing three frailty categories was 28.5% (three 
studies, 95%CI=8.6%-54.3%, data not shown in Figure) The random-effects models were 
used for these pooled analyses due to the high degree of heterogeneity observed (I2 
value=84.2%-96.5%). (Figure 2) 
 
DISCUSSION  
This systematic review and meta-analysis study identified five studies including 534 patients 
with Alzheimer’s disease with probable mild to moderate severity and showed that the pooled 
estimate of frailty prevalence was 31.9%. Although frailty was, as expected, more prevalent 
in patients with Alzheimer’s disease than in the general elderly population in the 
community,[18; 32] the prevalence rate appears comparable with or lower than those of other 
selected populations. For instance, previous systematic reviews have showed a median 
prevalence of 32% (range 11%-78%) in cancer patients,[33] pooled prevalence of 36.8% 
(95% CI = 29.9-44.1%,) and 67.0% (95% CI = 58.7-74.7%) in patients with end-stage renal 
disease according to the objectively measured and self-reported CHS criteria, 
respectively,[34] and pooled mean prevalence of 52.3% (95%CI=37.9%-66.5%) in nursing 
home patients.[35]  
 
It is of note that approximately 30% of patients with Alzheimer’s disease were classified as 
physically robust with no frailty criteria components. Similar to the general elderly 
population,[36] frailty status changed dynamically as shown in a longitudinal study 
examining the frailty transition over one year among cognitively impaired community-
dwelling older people.[37] In this study, frailty worsened in almost half of patients with mild 
to moderate Alzheimer’s disease while approximately 17% of them improved their frailty 
status.[37] These findings suggest that frailty could potentially be targeted by interventions, 
such as an exercise program,[38; 39] to reduce related adverse outcomes[27; 30] in frail 
individuals with Alzheimer’s disease. 
 
Frailty and Alzheimer’s disease share multiple etiologies, features, and related factors. For 
example, both frailty and Alzheimer’s disease share a wide range of risk factors, including 
advanced age, female gender, low physical activity, low education, low wealth, depression, 
diabetes, and inflammation.[40; 41] Both entities are also associated with adverse health 
outcomes. Although frailty and Alzheimer’s disease do not co-exist in all cases, multiple 
shared factors, a high co-occurrence rate, and apparent bidirectional causal associations may 
raise the possibility that frailty and Alzheimer’s disease may have the same pathophysiology. 
Recent studies from the Rush Memory and Aging Project showed novel associations of 
Alzheimer’s disease pathology with frailty.[42; 43] Postmortem Alzheimer’s disease 
pathology has been significantly associated with a presence of frailty proximate to death[42] 
as well as a more rapid progression of frailty before death.[43] 
 
The findings of this review should be interpreted with caution due to some limitations. First, 
the true prevalence of frailty among patients with Alzheimer’s disease is expected to be much 
higher as end-stage patients may not be able to participate in studies or perform 
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measurements of physical frailty components due to severe cognitive and/or physical 
limitations. Three of the five included studies excluded patients with severe cognitive 
impairment: Mini-Mental State Examination (MMSE)<10 or Clinical Dementia Rating 
(CDR)=3,[29] MMSE<18,[27] and MMSE<15,[30] while the other two studies did not make 
exclusion criteria based on disease severity.[28; 31] Therefore, generalization of the findings 
of the current review would be limited to older people with mild to moderate Alzheimer’s 
disease. Second, the number of studies included in the meta-analysis was only five and 
sample sizes of these studies were small (n=38-207), leading to a wide 95% confidence 
interval of the pooled prevalence (15.7%-48.5%). Third, two studies[30; 31] classified frailty 
in a dichotomous manner (YES/NO) while the other three[27-29] classified in three 
categories (robust, pre-frail and frail). This could potentially cause a bias in overall 
prevalence of frailty. 
 
This review is still useful as patients with mild to moderate Alzheimer’s disease are often 
targeted in dementia research. Another potential limitation is that all studies included in the 
meta-analysis used modified versions of the frailty criteria apparently due to the availability 
of data, as is often the case with other frailty studies.[44] It should be noted that these 
modifications may have significant impacts on outcomes.[44] 
 
This review’s findings on frailty status in the Alzheimer’s disease population are important 
for clinicians and researchers. Clinicians, especially primary care practitioners, are currently 
encouraged to identify dementia earlier in its trajectory,[45; 46] and should be aware that one 
in three cases perceived as mild to moderate will also have physical frailty features. 
Therefore, comprehensive assessment should be part of the dementia recognition process.[47] 
Furthermore, identifying high risk individuals with both Alzheimer’s disease and frailty[27; 
30] may contribute to better care because these patients could potentially be targeted for 
interventions, or offered palliative care if necessary.[48] Researchers studying interventions 
early in the dementia trajectory should also be aware that physical frailty may limit their 
interventions, such as an exercise program[49]. Future research is warranted to examine 
frailty status of patients with Alzheimer’s disease in different disease stages, including those 
with severe cognitive impairment. 
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Figure 1. Systematic review flow chart of study selection process 
 
 
  2,564 studies identified through database searching 
   Embase (n=1,127) 
   MEDLINE (n=1,026) 
   CINAHL Plus (n=218) 
   PsycINFO (n=147) 
   Cochrane Library (n=46) 
 
2 additional studies identified through 
other sources 
1,734 studies screened for titles and abstracts 
21 studies for full-text review 
Total of 2,566 studies identified 
832 duplicated studies excluded 
1,713 studies excluded by screening title 
(n=1,685) and abstract (n=28) 
 
5 studies for methodological quality assessment 
16 studies excluded by full-text review 
   Editorial/review/comment/poster (n=9)  
   Same cohort but smaller size (n=3) 
   Frailty not categorized (n=2) 
   Data of interest not shown (n=2) 
 
5 studies for meta-analysis 
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Table 1. Summary of studies on prevalence of frailty status in patients with Alzheimer’s disease. 
Author/Study Year Location Sample 
Diagnostic 
criteria 
Mean age* 
(range) 
Female* 
(%) 
Frailty 
criteria 
Robust 
(%) 
Pre-frailty 
(%) 
Frailty 
(%) 
Quality 
score† 
Tay et al[31] 2016 Singapore 
n=83 recruited from memory clinic 
Exclusion: possible AD, stroke, Parkinson’s disease, subdural 
hematoma, normal pressure hydrocephalus, brain tumor, 
hypothyroidism, B12 deficiency, hypercalcemia, any active 
neuropsychiatric conditions 
NINCDS-
ADRDA 
76.6 
(>55) 
64.6% mCHS 
65 
(78.3%) 
- 
18 
(21.7%) 
4/6 
Kulmala et al[28] 
GeMS 
2014 Finland 
n=97 random sample from the community 
Exclusion: not documented 
DMS-IV 
82 
(76-100) 
69.6% mCHS 
23 
(23.7%) 
46 (47.4%) 
28 
(28.9%) 
4/6 
Oosterveld et 
al[29] 
4C-Dementia 
2014 Netherlands 
n=207 recruited from memory clinics 
Exclusion: MMSE<10, CDR=3 
NINCDS-
ADRDA 
75 
(-) 
57.7% mCHS 
82 
(39.6%) 
102 
(49.3%) 
23 
(11.1%) 
4/6 
Bilotta et al[27] 2012 Italy 
n=109 recruited from geriatric outpatient service 
Exclusion: MMSE<18 
DMS-IV 
82.8 
(>65) 
77.1% mSOF 
25 
(22.9%) 
30 
(27.5%) 
54 
(49.5%) 
4/6 
Solfrizzi et al[30] 
ILSA 
2012 Italy 
n=38 random sample from the community 
Exclusion: MMSE<15 
NINCDS-
ADRDA 
73.1 
(65-84) 
45.2% mCHS 
19 
(50.0%) 
- 
19 
(50.0%) 
5/6 
* Mean age and female proportion of cohort of interest, or entire cohort 
† Methodological quality score. 
4C-Dementia: Clinical Course of Cognition and Comorbidity-Dementia Study 
AD: Alzheimer’s disease 
CDR: Clinical Dementia Rating 
DMS: Diagnostic and Statistical Manual of Mental Disorders 
GeMS: Geriatric Multidisciplinary Strategy for the Good Care of the Elderly Study 
ILSA: Italian Longitudinal Study on Aging 
mCHS: Modified Cardiovascular Health Study criteria 
MMSE: Mini-Mental State Examination 
mSOF: Modified Study of Osteoporotic Fractures frailty index 
NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders 
Association 
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Table 2. Methodological quality of the included studies according to a tool for critically appraising studies of prevalence or incidence of a health 
problem.* 
Study 1 2 3 4 5 6 
Quality 
score 
Tay et al 1 1 0 1 1 0 4/6 
Kulmala et al 1 1 0 1 1 0 4/6 
Oosterveld et al 1 1 0 1 1 0 4/6 
Bilotta et al 1 1 0 1 1 0 4/6 
Solfrizzi et al 1 1 0 1 1 1 5/6 
* 
1) Are the study design and sampling method appropriate for the research question?  
2) Is the sampling frame appropriate?  
3) Is the sample size adequate?  
4) Are objective, suitable and standard criteria used for measurement of the health outcome?  
5) Is the health outcome measured in an unbiased fashion?  
6) Is the response rate adequate? Are the refusers described? 
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Figure 2. Forest plots of prevalence of (A) frailty, (B) pre-frailty, and (C) robustness among 
patients with Alzheimer’s disease. 
A Frailty 
 
Pooled prevalence: 31.9% (95%CI=15.7%-48.5%) 
Heterogeneity: p<0.0001, I2=94.1% 
 
B Pre-frailty* 
 
* Only studies that provided three frailty categories (robust, pre-frail, and frail) were 
included. 
Pooled prevalence: 41.4% (95%CI=28.3%-55.2%) 
Heterogeneity: p=0.0004, I2=87.0% 
 
 
 
C Robust* 
 
* Only studies that provided three frailty categories (robust, pre-frail, and frail) were 
included. 
Pooled prevalence: 29.0% (95%CI=18.4%-40.9%) 
Heterogeneity: p<0.001, I2=84.2% 
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8
combined 0.31 (0.16, 0.49)
Solfrizz i 2012 0.50 (0.33, 0.67)
Bilotta 2012 0.50 (0.40, 0.59)
Oosterveld 2014 0.11 (0.07, 0.16)
Kulmala 2014 0.29 (0.20, 0.39)
Tay 2016 0.22 (0.13, 0.32)
proportion (95% confidence interval)
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6
combined 0.41 (0.28, 0.55)
Bilotta 2012 0.28 (0.19, 0.37)
Oosterveld 2014 0.49 (0.42, 0.56)
Kulmala 2014 0.47 (0.37, 0.58)
proportion (95% confidence interval)
Proportion meta-analysis plot [random effects]
0.1 0.2 0.3 0.4 0.5
combined 0.29 (0.18, 0.41)
Bilotta 2012 0.23 (0.15, 0.32)
Oosterveld 2014 0.40 (0.33, 0.47)
Kulmala 2014 0.24 (0.16, 0.33)
proportion (95% confidence interval)
